公开(公告)号：US10308690B2

公开(公告)日：2019-06-04

申请号：US14961164

申请日：2015-12-07

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Gustav Rodrigo ,  Mats Ander ,  Göran Baurén ,  Tomas Björkman

IPC: C07K14/31 ,  B01J20/32 ,  B01D15/38 ,  C07K1/22 ,  B01J20/286 ,  C07K14/745 ,  C07K16/00

Abstract: The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, comprising at least the mutation wherein the glutamine residue at position 9 has been mutated to a tryptophan, leucine, glutamic acid, valine or lysine. The invention also discloses multimers of the polypeptide, as well as separation matrices comprising the multimers or polypeptides.

公开(公告)号：US20190144511A1

公开(公告)日：2019-05-16

申请号：US16252015

申请日：2019-01-18

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Gustav Rodrigo ,  Mats Ander ,  Tomas Bjorkman

IPC: C07K14/195 ,  C07K16/00 ,  C07K1/22

Abstract: A kappa light chain-binding polypeptide comprising or consisting essentially of one or more mutated binding domains of Peptostreptococcus Protein L.

公开(公告)号：US10112980B2

公开(公告)日：2018-10-30

申请号：US15598685

申请日：2017-05-18

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Mats Ander ,  Goran Bauren ,  Tomas Bjorkman ,  Gustav Rodrigo

IPC: C07K14/31 ,  C07K14/745 ,  C07K16/00 ,  C07K1/22 ,  B01D15/38 ,  B01J20/32 ,  B01J20/286

Abstract: The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamic acid residue at position 15 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.

公开(公告)号：US20170320919A1

公开(公告)日：2017-11-09

申请号：US15526895

申请日：2015-12-11

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Gustav Rodrigo ,  Mats Ander ,  Tomas Bjorkman

IPC: C07K14/195

CPC classification number: C07K14/195 ,  C07K1/22 ,  C07K16/00 ,  C07K2317/55 ,  C07K2317/569 ,  C07K2319/02

Abstract: The invention discloses kappa light chain-binding polypeptide comprising a mutated binding domain of Peptostreptococcus protein L, wherein at least one asparagine residue of a parental domain defined by, or having at least 95% or 98% sequence homology with, SEQ ID NO: 2-6 or 2 has been mutated to another amino acid residue which is not asparagine, proline or cysteine.

公开(公告)号：US10730908B2

公开(公告)日：2020-08-04

申请号：US15798784

申请日：2017-10-31

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Annika Forss ,  Mats Ander ,  Tomas Bjorkman ,  Hans Blom ,  Jesper Hansson ,  Gustav Rodrigo

IPC: C07K1/16 ,  B01D15/08 ,  C07K1/22 ,  C07K16/00 ,  B01J20/286 ,  B01J20/285 ,  B01D15/18 ,  B01D15/34 ,  C07K14/31

Abstract: The invention relates to a method of isolating an immunoglobulin, comprising the steps of: a) providing a separation matrix comprising at least 15 mg/ml multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support, wherein the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml; b) contacting a liquid sample comprising an immunoglobulin with the separation matrix; c) washing the separation matrix with a washing liquid; d) eluting the immunoglobulin from the separation matrix with an elution liquid; and e) cleaning the separation matrix with a cleaning liquid comprising at least 0.5 M NaOH.

公开(公告)号：US10208091B2

公开(公告)日：2019-02-19

申请号：US15526849

申请日：2015-12-11

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Gustav Rodrigo ,  Mats Ander ,  Tomas Bjorkman

IPC: C07K14/195 ,  C07K1/22 ,  C07K16/00

Abstract: A kappa light chain-binding polypeptide comprising or consisting essentially of one or more binding domains of Peptostreptococcus Protein L, each of said domains being selected from the group consisting of domain 2, domain 3 and domain 4.

公开(公告)号：US20180327512A1

公开(公告)日：2018-11-15

申请号：US15525688

申请日：2015-11-11

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Gustav Rodrigo ,  Tomas Bjorkman ,  Mats Ander

IPC: C07K16/46 ,  B01J20/289 ,  B01J20/32 ,  B01D15/38

CPC classification number: C07K16/46 ,  B01D15/3809 ,  B01J20/289 ,  B01J20/3219 ,  B01J20/3274 ,  C07K1/22 ,  C07K14/31 ,  C07K16/00 ,  C07K16/065

Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO 26 or SEQ ID NO 27, wherein at least the alanine residue at the position corresponding to position 42 in SEQ ID NO:4-7 has been mutated to arginine and/or wherein at least the aspartic acid residue at the position corresponding to position 37 in SEQ ID NO:4-7 has been mutated to glutamic acid.

公开(公告)号：US20170334954A1

公开(公告)日：2017-11-23

申请号：US15526941

申请日：2015-11-16

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Gustav Rodrigo ,  Tomas Bjorkman ,  Mats Ander

IPC: C07K14/31 ,  B01D15/38 ,  C07K1/22 ,  C07K16/00

CPC classification number: C07K16/46 ,  B01D15/3809 ,  B01J20/289 ,  B01J20/3219 ,  B01J20/3274 ,  C07K1/22 ,  C07K14/31 ,  C07K16/00 ,  C07K16/065

Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO 51 or SEQ ID NO 52 wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO:4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.

公开(公告)号：US20200079878A1

公开(公告)日：2020-03-12

申请号：US16594731

申请日：2019-10-07

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Gustav Rodrigo ,  Tomas Bjorkman ,  Mats Ander

IPC: C07K16/46 ,  C07K16/00 ,  C07K14/31 ,  C07K1/22 ,  C07K16/06 ,  B01D15/38 ,  B01J20/32 ,  B01J20/289

Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO 51 or SEQ ID NO 52 wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO:4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.

公开(公告)号：US20190381480A1

公开(公告)日：2019-12-19

申请号：US16486653

申请日：2018-02-15

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Ronnie Palmgren ,  Jean-Luc Maloisel ,  Gustav Rodrigo ,  Tomas Bjorkman

IPC: B01J20/286 ,  B01D15/38 ,  B01J20/28 ,  B01J20/32 ,  B01D15/18 ,  C07K1/22

Abstract: A separation matrix comprising porous particles to which antibody-binding protein ligands have been covalently immobilized, wherein the density of said ligands is above 5 mg/ml, the volume-weighted median diameter of said porous particles is at least 10 and below 30 μm and the said porous particles have a gel phase distribution coefficient, expressed as KD for dextran of molecular weight 110 kDa, of 0.5-0.9.